Results 11 to 20 of about 46,962 (257)

Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Gangadaran N, Mamlekar H, Saha S, Kashyap R, Yadav S, Rahman K, Gupta R, Vijayaran M, Singh M, Chandra D.   +9 more
europepmc   +2 more sources

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review

Therapeutic Advances in Respiratory Disease, 2022
Dasatinib, a tyrosine kinase inhibitor, is usually prescribed for chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. However, some patients may develop an intolerance to this drug over the years.
Sang-A Kim, Byoung Soo Kwon, Jin-Haeng Chung, Ji Yun Lee, Soo-Mee Bang, Jeong-Ok Lee   +5 more
doaj   +1 more source

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

Frontiers in Oncology, 2023
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib.
Fang Cheng, Fang Cheng, Qiling Xu, Qiling Xu, Qiang Li, Qiang Li, Zheng Cui, Zheng Cui, Weiming Li, Fang Zeng, Fang Zeng   +10 more
doaj   +1 more source

FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC/FAK/RHO/ROCK-dependent pathway [PDF]

, 2017
Deregulated SRC/FAK signaling leads to enhanced migration and invasion in many types of tumors. In myxoid and round cell liposarcoma (MRCLS), an adipocytic tumor characterized by the expression of the fusion oncogene FUS-CHOP, SRC have been found as one ...
González, M. Victoria, Hermida Prado, Francisco, Singh Singh, Ranjit, Tornin Cavielles, Juan   +3 more
core   +2 more sources

MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. [PDF]

PLoS ONE, 2013
Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib.
Yanfen Fang, Like Zhong, Meihua Lin, Xinglu Zhou, Hui Jing, Meidan Ying, Peihua Luo, Bo Yang, Qiaojun He   +8 more
doaj   +1 more source

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J., Granchi, C., Knight, J.R.P., Milner, J., Minutolo, F., Phillips, R.M., Rani, R.   +6 more
core   +1 more source

Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]

, 2020
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGFβ
A Rojas-Fernandez, A Woods, AR Ramjaun, AY Hsing, B Bierie, B Ozdamar, B-C Kim, BR Binder, C Allan, CJ David, CS Hill, DB Shackelford, EC Connolly, FA Ran, G Avery-Cooper, G Rena, G Rosti, GD Cuny, GJ Inman, GJ Inman, GM Keating, H Ikushima, J Massagué, J Massagué, J Massaous, J Ozanne, J Song, J Vogt, J Xu, JF Callahan, JL Wrana, JM Lizcano, Joan Massagué, JY Altarejos, K Clark, KA Brown, KJ Livak, LC Spender, LC Spender, M Abe, M Kowanetz, M Tojo, MO Li, MR Keeton, NJ Bright, P Lönn, PH Lin, PK Datta, PM Siegel, RJ Akhurst, RJ Akhurst, S DaCosta Byfield, S Dennler, S Edlund, S Strickson, SA Hawley, T Sonntag, TB Sundberg, Y Drabsch, Y Liu, Y Shi, Y Yang, Y Zhang, Y Zhang   +63 more
core   +2 more sources

Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells

Neoplasia: An International Journal for Oncology Research, 2012
Epidermal growth factor receptor (EGFR) is an important oncoprotein that promotes cell growth and proliferation. Dasatinib, a bcr-abl inhibitor, has been approved clinically for the treatment of chronic myeloid leukemia and demonstrated to be effective ...
Yu-Chin Lin, Meng-Hsuan Wu, Tzu-Tang Wei, Shu-Hui Chung, Kuen-Feng Chen, Ann-Lii Cheng, Ching-Chow Chen   +6 more
doaj   +1 more source

Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients [PDF]

, 2016
Background: 8000 cases of renal cancer are diagnosed each year in the UK, with a five-year survival rate of 50 %. Treatment options are limited; a potential therapeutic target is the Src family kinases (SFKs).
Aitchison, Michael, Edwards, Joanne, Fraser, Siobhan, Hammond, Rachel, Jones, Robert J., Lim, Zhi, MacDonald, Alasdair I., Oades, Grenville M., Qayyum, Tahir, Roseweir, Antonia K.   +9 more
core   +1 more source

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency

HemaSphere, 2018
. Dasatinib is an ABL1 tyrosine kinase inhibitor (TKI) with a short in vivo plasmatic half-life but with good efficiency, which is not fully understood.
Kelly Airiau, Béatrice Turcq, Stéphane Bouchet, Elodie Laharanne, Jean-Philippe Vial, Gabriel Etienne, François-Xavier Mahon, Francis Belloc   +7 more
doaj   +1 more source